C07C237/42

COMPOUND AS A UBR BOX DOMAIN LIGAND

The present specification relates to a compound as a UBR box domain ligand. The present specification provides a small molecule compound that binds to the UBR box domain. Further, the present specification provides a composition for inhibiting UBR box domain substrate binding, including a ligand compound that binds to a UBR box domain, a pharmaceutical composition for treating UBR-related disease, and a use thereof.

COMPOUND AS A UBR BOX DOMAIN LIGAND

The present specification relates to a compound as a UBR box domain ligand. The present specification provides a small molecule compound that binds to the UBR box domain. Further, the present specification provides a composition for inhibiting UBR box domain substrate binding, including a ligand compound that binds to a UBR box domain, a pharmaceutical composition for treating UBR-related disease, and a use thereof.

Insecticidal compounds

The present invention relates to novel triazole derivatives of formula (I) having insecticidal activity, to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests ##STR00001## wherein Y, X.sub.1, X.sub.2 and Q are as defined in claim 1; or salts thereof.

Insecticidal compounds

The present invention relates to novel triazole derivatives of formula (I) having insecticidal activity, to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests ##STR00001## wherein Y, X.sub.1, X.sub.2 and Q are as defined in claim 1; or salts thereof.

Inhibitors of histone deacetylase

The present invention relates to compounds of formula (I): ##STR00001##
or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, W.sub.1, W.sub.2, W.sub.3, and W.sub.4 are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting β-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation. Compounds of the invention are useful for treating, alleviating, and/or preventing various conditions, including for example, a metabolic disorder such as type 1 or type 2 diabetes, dyslipidemias, lipodystrophies, liver disease associated with metabolic syndrome, polycystic ovarian syndrome, or obesity; inflammatory disease; neurological disorder; a memory or cognitive function disorder/impairment; an extinction learning disorder; fungal disease or infection; viral disease or infection such as HIV; hematological disease; liver disease; lysosomal storage disease; or neoplastic disease in humans or animals.

Inhibitors of histone deacetylase

The present invention relates to compounds of formula (I): ##STR00001##
or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, W.sub.1, W.sub.2, W.sub.3, and W.sub.4 are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting β-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation. Compounds of the invention are useful for treating, alleviating, and/or preventing various conditions, including for example, a metabolic disorder such as type 1 or type 2 diabetes, dyslipidemias, lipodystrophies, liver disease associated with metabolic syndrome, polycystic ovarian syndrome, or obesity; inflammatory disease; neurological disorder; a memory or cognitive function disorder/impairment; an extinction learning disorder; fungal disease or infection; viral disease or infection such as HIV; hematological disease; liver disease; lysosomal storage disease; or neoplastic disease in humans or animals.

TERTIARY AMINE DERIVATIVES AND THEIR USES FOR TREATING A VIRAL INFECTION
20220251028 · 2022-08-11 ·

The present invention relates to a new class of tertiary amine derivatives of formula (I) and their uses for treating viral infections, particularly viral respiratory infections. The present invention further relates to pharmaceutical compositions comprising compounds of formula (I).

TERTIARY AMINE DERIVATIVES AND THEIR USES FOR TREATING A VIRAL INFECTION
20220251028 · 2022-08-11 ·

The present invention relates to a new class of tertiary amine derivatives of formula (I) and their uses for treating viral infections, particularly viral respiratory infections. The present invention further relates to pharmaceutical compositions comprising compounds of formula (I).